Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Jeremy_Bender
|
| gptkbp:clinicalTrialPhase |
gptkb:FIREFLY-1
gptkb:FIREFLY-2 |
| gptkbp:focusesOn |
pediatric cancer therapies
|
| gptkbp:foundedYear |
2018
|
| gptkbp:founder |
gptkb:Jeremy_Bender
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Day One Biopharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mission |
developing new therapies for children with cancer
|
| gptkbp:notableProduct |
gptkb:tovorafenib
|
| gptkbp:numberOfEmployees |
approximately 100 (as of 2023)
|
| gptkbp:specializesIn |
targeted therapies for pediatric patients
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:DAWN
|
| gptkbp:website |
https://www.dayonebio.com/
|
| gptkbp:bfsParent |
gptkb:Canaan_Partners
|
| gptkbp:bfsLayer |
6
|